News and Press Releases
Check out our latest news.
All
News
·
Kira Pharmaceuticals
Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA (January 5, 2023) – Kira
Pharmaceuticals, a global biotechnology company
pioneering transformational complement therapies to
treat immune-mediated diseases, today announced that
Frederick Beddingfield M.D., Ph.D., Chief... Read more
Jan 05, 2023
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(December 20, 2022) – Kira Pharmaceuticals, a global
biotechnology company pioneering transformational
complement therapies to treat immune-mediated
diseases, announced today that the Chinese... Read more
Dec 20, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, MA (November 30, 2022) – Kira
Pharmaceuticals, a global biotechnology company
pioneering transformational complement therapies to
treat immune-mediated diseases, today announced that
the first cohort has been dosed in a Phase 2... Read more
Nov 30, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
Biomarker data demonstrates proof-of-concept for
KP104’s dual-targeting mechanism via dose-dependent
inhibition of alternative and terminal pathways and
supports intravenous and subcutaneous administration
of KP104 in phase 2 studies... Read more
Nov 03, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022
Phase 1 biomarker data confirms proof of mechanism
with dose-dependent and potent inhibition of
alternative and terminal pathways with KP104 via
dual-targeting mechanism Data demonstrated KP104 was
safe and well tolerated, and supports... Read more
Oct 17, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(October 17, 2022) – Kira Pharmaceuticals, a global
biotechnology company pioneering transformational
complement therapies to treat immune-mediated
diseases, announced today that the Chinese... Read more
Oct 16, 2022
News
·
Kira Pharmaceuticals
Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA (January 5, 2023) – Kira
Pharmaceuticals, a global biotechnology company
pioneering transformational complement therapies to
treat immune-mediated diseases, today announced that
Frederick Beddingfield M.D., Ph.D., Chief... Read more
Jan 05, 2023
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(December 20, 2022) – Kira Pharmaceuticals, a global
biotechnology company pioneering transformational
complement therapies to treat immune-mediated
diseases, announced today that the Chinese... Read more
Dec 20, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, MA (November 30, 2022) – Kira
Pharmaceuticals, a global biotechnology company
pioneering transformational complement therapies to
treat immune-mediated diseases, today announced that
the first cohort has been dosed in a Phase 2... Read more
Nov 30, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
Biomarker data demonstrates proof-of-concept for
KP104’s dual-targeting mechanism via dose-dependent
inhibition of alternative and terminal pathways and
supports intravenous and subcutaneous administration
of KP104 in phase 2 studies... Read more
Nov 03, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022
Phase 1 biomarker data confirms proof of mechanism
with dose-dependent and potent inhibition of
alternative and terminal pathways with KP104 via
dual-targeting mechanism Data demonstrated KP104 was
safe and well tolerated, and supports... Read more
Oct 17, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(October 17, 2022) – Kira Pharmaceuticals, a global
biotechnology company pioneering transformational
complement therapies to treat immune-mediated
diseases, announced today that the Chinese... Read more
Oct 16, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, MA (October 13, 2022) – Kira
Pharmaceuticals, a global biotechnology company
pioneering transformational complement therapies to
treat immune-mediated diseases, today announced
participation in the 2nd Annual Needham Biotech... Read more
Oct 13, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)
Phase 1 supporting data indicated an encouraging
profile and confirmed the dual mechanism of action
achieved through targeting both the alternative and
terminal complement pathways CAMBRIDGE, MA (October
3, 2022) – Kira Pharmaceuticals, a... Read more
Oct 03, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Oral presentation characterizes promising PK/PD
properties of KP104 in relevant animal models and
supports its further development as a potent
bifunctional complement inhibitor suitable for both
intravenous and subcutaneous administration... Read more
Aug 26, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(August 1, 2022) – Kira Pharmaceuticals, a global
clinical-stage biotechnology company pioneering
transformational complement therapies to treat
immune-mediated diseases, today announced the... Read more
Aug 01, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (July
28, 2022) – Kira Pharmaceuticals, a global
clinical-stage biotechnology company pioneering
transformational complement therapies to treat
immune-mediated diseases, today announced that... Read more
Jul 28, 2022
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(November 16, 2021) – Kira Pharmaceuticals, a global
biotechnology company pioneering transformational
complement-targeted therapies to treat
immune-mediated diseases, today announced the... Read more
Nov 12, 2021
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA
(February 23, 2021)CAMBRIDGE, MA, USA and SUZHOU,
JIANGSU, CHINA (February 23, 2021) – Kira
Pharmaceuticals, a global biotechnology company
pioneering a new generation of
complement-targeted... Read more
Feb 22, 2021
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
CAMBRIDGE, MA and SUZHOU, JIANGSU (February 2, 2021)
– Kira Pharmaceuticals, a global biotechnology
company pioneering a new generation of
complement-targeted therapies to treat
immune-mediated diseases, announced today that the
first... Read more
Feb 01, 2021
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA and SUZHOU, China (January 12, 2021) –
Kira Pharmaceuticals, a global biotechnology company
pioneering a new generation of complement-targeted
therapies to treat immune-mediated diseases, today
announced that Frederick... Read more
Jan 12, 2021
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
CAMBRIDGE, MA and SUZHOU, China (January 7, 2021) –
Kira Pharmaceuticals, a global biotechnology company
pioneering a new generation of complement-targeted
therapies to treat immune-mediated diseases, today
announced the first closing of... Read more
Jan 07, 2021
News
·
Kira Pharmaceuticals
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
– $46M in Financing Secured from Leading Global Life
Science Investors – Frederick Beddingfield Appointed
as CEO CAMBRIDGE, MA and SUZHOU, China (November 12,
2020) – Kira Pharmaceuticals, a global biotechnology
company pioneering a new... Read more
Nov 11, 2020
1
of
3
Get in touch with us!
Get in touch to learn more about our LOGIC discovery
platform and pipeline.